To the Editor:

Systemic mastocytosis (SM) is a myeloproliferative disorder characterized by extreme heterogeneity of clinical manifestations, course and prognosis. According to the WHO 2016 classification, selected clinical findings are useful for distinguishing aggressive from indolent variant, a distinction that drives therapeutic decisions^[@CR1]^. Additional clinical and laboratory variables were then shown to correlate with survival, including advanced age, elevated beta-2-microglobulin and alkaline phosphatase (ALP) levels^[@CR2],[@CR3]^. Also, mutations of selected genes, usually associated with "high risk" features in other myeloid neoplasms^[@CR4],[@CR5]^, were identified, that provide clinically relevant information about disease' course; in particular, mutation in *SRSF2*, *ASXL1*, *RUNX1*, and *CBL* were shown to be prognostically relevant^[@CR6]--[@CR8]^, and were also validated recently in our patients' cohort^[@CR9]^. Conversely, unlike other myeloproliferative neoplasm, particularly myelofibrosis^[@CR10]^, cytogenetic abnormalities in patients with SM are infrequent and have poor prognostic relevance^[@CR11]^. By integrating the above prognostically relevant clinical and molecular parameters in a large cohort of SM patients seen at Mayo Clinic (*n* = 580), Pardanani et al. recently derived two prognostic models that may find wide clinical application: the first one was based upon clinical parameters only, the second enlisted both clinical and genomic findings^[@CR9]^. Variables enlisted in the clinical model include SM variant (advanced versus indolent/smouldering SM), age \> 60 years, platelets \< 150 × 10^9^/L, sex-adjusted anemia and serum alkaline phosphatase above normal range, that are complemented by adverse mutations (*ASXL1, RUNX1, NRAS*) in the hybrid clinical-molecular score.

The aim of the current study was to assess the performance of the Mayo Alliance Prognostic System (MAPS) models in a real-life setting at our Center. After approval from the institutional review board, we interrogated our database for the availability of MAPS-related parameters, and finally applied the clinical-only model to 94 SM patients and the hybrid clinical-molecular model to 65 patients, out of a total of 127 patients with diagnosis of SM observed in the period from 2000 to 2018; information was last updated in August 2018.

Clinical and laboratory features of the study population are summarized in Table [1](#Tab1){ref-type="table"}. According to WHO classification^[@CR1]^, 82 of 94 (87.2%) patients were diagnosed with non-advanced forms, 78 (83.0%) were indolent and 4 (4.3%) smouldering SM. The 12 advanced cases included 9 aggressive variants (ASM, 9.6%), 2 with an associated hematological neoplasm (SM-AHN, 2.1%), and 1 mast cell leukemia (MCL, 1.1%). As expected from other reports in larger cohorts, compared with advanced SM, the patients with indolent/smouldering SM were younger, had higher hemoglobin and platelet count, lower leukocyte count, and lower levels of serum alkaline phosphatase and tryptase. Overall, 98% of the patients were found positive for the *KIT*D816V mutation. Additional myeloid mutations (*ASXL1, RUNX1*, and *SRSF2*) were assessed in 65 patients; for 21 of them, genotyping of *NRAS* was also available. Overall, we observed 6 cases with high risk mutations, all of which were included among advanced forms. The rate of adverse mutations (9.2%) was lower that reported by Pardanani and colleagues (21%), and is likely to be accounted for by a greater representation of advanced forms in their database. Fifty-eight percent of patients with advanced SM died, after a median follow-up of 23 months, as compared to 1.2% of indolent/smouldering SM, after a median follow-up of 50 months (*P* \< 0.001).Table 1Clinical and laboratory features of 94 patients with systemic mastocytosis (SM) included in the studyVariablesOverall *n* = 94Indolent/smouldering SM *N* = 82Advanced SM *N* = 12*p* valueMedian age (range)47 (17--80)45 (17--80)64 (23--78)**0.01**Age \> 60 years; *n* (%)26 (27.7)19 (23.2)7 (58.3)**0.017**Hemoglobin, g/dl, median (range)13.7 (4.8--16.2)14.2 (10.1--19.4)11.1 (5.1--17.4)**\<0.001**Anemia sex adjusted; *n* (%)22 (23.4)11 (13.4)11 (91.7)**\<0.001**Leukocyte count x 10^9^/l, median (range)7.3 (2.0--39.8)7.1 (3.2--17.1)12.1 (2.0--39.8)**0.022**Platelet count x 10^9^/l, median (range)232 (70--421)263 (98--456)79 (10--368)**\<0.001**Platelet count \< 150 × 10^9^/l; *n* (%)14 (14.8)3 (3.7)10 (83.3)**\<0.001**Serum tryptase ng/ml; median (range)33.0 (3.1--7180)29.0 (3.0--591)162.5 (30.0--7180)**\<0.01**Serum ALP, U/l; median (range)75 (20--184)90 (31--280)148.5 (20--438)**0.004**Serum ALP \> UNL; *n* (%)21 (22.3)14 (17.1)7 (58.3)**\<0.001***KITD816V; n* (%) *N* *=* *88*86 (97.7)75 (97.4) *N* Evaluable = 7711 (100) *N* Evaluable = 111.0*ASXL1* mutated; *n* (%) *N* *=* *65*3 (4.6)0 (0) *N* Evaluable = 553 (30) *N* Evaluable = 10**0.003***RUNX1* mutated; *n* (%) *N* *=* *65*1 (1.5)0 (0) *N* Evaluable = 551 (10) *N* Evaluable = 100.154*NRAS* mutated; *n* (%) *N* *=* *21*10 (0) *N* Evaluable = 161 (25) *N* Evaluable = 50.238*SRSF2* mutated; *n* (%) *N* *=* *65*1 (1.5)0 (0) *N* Evaluable = 551 (10) *N* Evaluable = 100.154Adverse mutations; *n* (%) *N* *=* *65*6 (9.2)0 (0) *N* Evaluable = 556 (50) *N* Evaluable = 10**\<0.001**Median follow-up in months (range)46 (2.1--209)50.1 (2.1--209)23.4 (2.1--115)**0.022**Deaths; *n* (%)8 (8.5)1 (1.2)7 (58.3)**\<0.001***SM* systemic mastocytosis, *SM-AHN* systemic mastocytosis with an associated hematological neoplasm, *ALP* alkaline phosphatase, *UNL* upper normal limit, *N* means the number of patients for which the particular information was available*p* values lower than significance threshold are highlighted by bold

Owing to the prevalence of indolent/smouldering cases in our cohort, we carried out a 3-tier stratification of patients according to the MAPS clinical and hybrid clinical-molecular model, by gathering patients with 1--2 and 3 to 5 risk factors in 2 categories only (intermediate and high risk, respectively) while patients with no risk factors were included in a low-risk category. Results of the analysis in our cohort excellently validated the performance of the MAPS score, overall resulting in a dramatic separation of patients with dismal overall survival (OS) and event-free survival (EFS) from others with very favorable course (Fig. [1](#Fig1){ref-type="fig"}). In particular, both models were able to identify an adverse risk category, with a median OS of only 18.8 months (95% CI, 0.1--48), significantly shorter than the intermediate and low-risk categories (OS not reached in both) (Fig.[1a, c](#Fig1){ref-type="fig"} for the clinical-only and hybrid model, respectively); the lack of a significant difference between low- and intermediate-risk patients can reasonably be ascribed to the limited number of events in our cohort mainly including not aggressive forms of SM, as exemplified by separate analysis of indolent/smouldering cases (Fig. [1b, d](#Fig1){ref-type="fig"} for the 2 models)Fig. 1The panels from (**a**--**d**) illustrate the performance of the Mayo clinical-only score (**a**, **b**) and the hybrid clinical-molecular score (**c**, **d**) concerning overall survival for: the low, intermediate and high risk category (**a**, **c**), and the low and intermediate-risk category only (**b**, **d**). The panels from (**e**--**h**) illustrate the impact of the Mayo scores regarding event-free survival in the different risk categories, as above

We also evaluated performance of the Mayo models using event-free survival (EFS) as an endpoint; events were death and progression from indolent to aggressive variant, that constitutes a major clinical event influencing long term outcome in SM (Fig. [1e--h](#Fig1){ref-type="fig"}). As shown in Fig. [1](#Fig1){ref-type="fig"}, the clinical-only model allowed prediction of shorter EFS in the entire cohort (*P* = 0.053; Fig. [1e](#Fig1){ref-type="fig"}) and, notably, in the indolent/smouldering cases (Fig. [1f](#Fig1){ref-type="fig"}; *P* = 0.048). The performance of the hybrid model at this regard was suboptimal, as it might be anticipated by the combined effects of limited number of cases and events (Fig. [1g, h](#Fig1){ref-type="fig"}).

In conclusion, this analysis allowed to confirm the general validity of risk stratification of patients with systemic mastocytosis according to the newly developed Mayo models; furthermore, we revealed its performance in predicting prognosis of intermediate category' patients, especially using the clinical model. The proportionality between risk factors and outcome reaffirms the proof-of-principle underneath Mayo model.

The easy and prompt attainability of parameters included in the clinical model makes this particularly suitable for routine patients' management. The use of the hybrid clinical-molecular model might be currently reserved to younger patients, where stem cell transplantation is an option, and should be definitely incorporated in clinical trials; also, it will be important to prospectively validate its performance in the era of new targeted agents like midostaurin^[@CR12]^. It is also conceivable that further insights into the mutation landscape of SM patients might lead to improvement of the hybrid clinical-molecular score, and making it more widely available and enhancing its performance.
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